We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Chevron, Roche Holding, General Electric, Centene and Carrier Global
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corp. (CVX - Free Report) , Roche Holding AG (RHHBY - Free Report) , General Electric Co. (GE - Free Report) , Centene Corp. (CNC - Free Report) and Carrier Global Corp. (CARR - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Chevron, Roche and General Electric
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corp. (CVX - Free Report) , Roche Holding AG (RHHBY - Free Report) and General Electric Co. (GE - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Chevron have modestly outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+46.0% vs. +44.8%) but they have handily outperformed the broader market.
The Zacks analyst sees Chevron as one of the best-placed global integrated oil firms to achieve sustainable production ramp-up. America’s No. 2 energy firm’s existing project pipeline is among the best in the industry, thanks to its premier position in the lucrative Permian Basin.
However, Chevron was not immune to the commodity price crash of 2020, forcing it to cut spending substantially. The company’s high oil price sensitivity will be a headwind should that scenario unfold again. Moreover, the supermajor’s 10-year reserve replacement ratio of 100% is indicative of its inability to replace the amount of oil and gas produced.
Shares of Roche have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-18.0% vs. +17.2%). The Zacks analyst believes that Roche’s performance in 2022 has been hit by significantly lower COVID-related sales in both divisions as the pandemic eased out. Sales of Actemra/RoActemra and Ronapreve (COVID-19) are declining with the pandemic weakening in several countries in 2022.
Nevertheless, strong demand for new drugs, namely Hemlibra (hemophilia), Ocrevus (multiple sclerosis), Evrysdi (spinal muscular atrophy), Phesgo (cancer) and Tecentriq (cancer), maintained momentum. The Diagnostics division also remained stable in terms of the growth of its routine business. However, competition is stiff for Tecentriq. The decline in sales of drugs like Herceptin, Avastin and MabThera will continue to drag sales down. Pipeline setbacks are a concern.
Shares of General Electric have outperformed the Zacks Diversified Operations industry over the past six months (+22.3% vs. +8.8%). The Zacks analyst believes that strong performance of the Aerospace and Healthcare segments is driving General Electric’s growth. Its investments in productivity and innovation should fuel growth going forward. Cost-control measures and pricing actions are aiding its bottom line. The company’s measures to reward its shareholders are encouraging.
However, supply chain disruptions, including labor and material shortages and high logistics costs are weighing on the company’s performance. Weakness in the Power and Renewable energy segment due to lower volumes is concerning. Foreign currency headwinds are hurting the company’s top line.
Other noteworthy reports we are featuring today include Centene Corp. (CNC - Free Report) and Carrier Global Corp. (CARR - Free Report) .
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Chevron, Roche Holding, General Electric, Centene and Carrier Global
For Immediate Release
Chicago, IL – December 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corp. (CVX - Free Report) , Roche Holding AG (RHHBY - Free Report) , General Electric Co. (GE - Free Report) , Centene Corp. (CNC - Free Report) and Carrier Global Corp. (CARR - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Chevron, Roche and General Electric
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corp. (CVX - Free Report) , Roche Holding AG (RHHBY - Free Report) and General Electric Co. (GE - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Chevron have modestly outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+46.0% vs. +44.8%) but they have handily outperformed the broader market.
The Zacks analyst sees Chevron as one of the best-placed global integrated oil firms to achieve sustainable production ramp-up. America’s No. 2 energy firm’s existing project pipeline is among the best in the industry, thanks to its premier position in the lucrative Permian Basin.
However, Chevron was not immune to the commodity price crash of 2020, forcing it to cut spending substantially. The company’s high oil price sensitivity will be a headwind should that scenario unfold again. Moreover, the supermajor’s 10-year reserve replacement ratio of 100% is indicative of its inability to replace the amount of oil and gas produced.
(You can read the full research report on Chevron here >>>)
Shares of Roche have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-18.0% vs. +17.2%). The Zacks analyst believes that Roche’s performance in 2022 has been hit by significantly lower COVID-related sales in both divisions as the pandemic eased out. Sales of Actemra/RoActemra and Ronapreve (COVID-19) are declining with the pandemic weakening in several countries in 2022.
Nevertheless, strong demand for new drugs, namely Hemlibra (hemophilia), Ocrevus (multiple sclerosis), Evrysdi (spinal muscular atrophy), Phesgo (cancer) and Tecentriq (cancer), maintained momentum. The Diagnostics division also remained stable in terms of the growth of its routine business. However, competition is stiff for Tecentriq. The decline in sales of drugs like Herceptin, Avastin and MabThera will continue to drag sales down. Pipeline setbacks are a concern.
(You can read the full research report on Roche here >>>)
Shares of General Electric have outperformed the Zacks Diversified Operations industry over the past six months (+22.3% vs. +8.8%). The Zacks analyst believes that strong performance of the Aerospace and Healthcare segments is driving General Electric’s growth. Its investments in productivity and innovation should fuel growth going forward. Cost-control measures and pricing actions are aiding its bottom line. The company’s measures to reward its shareholders are encouraging.
However, supply chain disruptions, including labor and material shortages and high logistics costs are weighing on the company’s performance. Weakness in the Power and Renewable energy segment due to lower volumes is concerning. Foreign currency headwinds are hurting the company’s top line.
(You can read the full research report on General Electric here >>>)
Other noteworthy reports we are featuring today include Centene Corp. (CNC - Free Report) and Carrier Global Corp. (CARR - Free Report) .
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.